Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Timothy P. DiPeri"'
Autor:
Turcin Saridogan, Argun Akcakanat, Ming Zhao, Kurt W. Evans, Erkan Yuca, Stephen Scott, Bryce P. Kirby, Xiaofeng Zheng, Min Jin Ha, Huiqin Chen, Patrick K. S. Ng, Timothy P. DiPeri, Gordon B. Mills, Jordi Rodon Ahnert, Senthil Damodaran, Funda Meric-Bernstam
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)
Abstract Several alterations in fibroblast growth factor receptor (FGFR) genes have been found in breast cancer; however, they have not been well characterized as therapeutic targets. Futibatinib (TAS-120; Taiho) is a novel, selective, pan-FGFR inhib
Externí odkaz:
https://doaj.org/article/54d8ba5ed19745f68237d1d74ca99a08
Autor:
Ming Zhao, Timothy P. DiPeri, Maria Gabriela Raso, Xiaofeng Zheng, Yasmeen Qamar Rizvi, Kurt W. Evans, Fei Yang, Argun Akcakanat, Marco Roberto Estecio, Debu Tripathy, Ecaterina E. Dumbrava, Senthil Damodaran, Funda Meric-Bernstam
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-14 (2023)
Abstract TROP2 antibody drug conjugates (ADCs) are under active development. We seek to determine whether we can enhance activity of TROP2 ADCs by increasing TROP2 expression. In metaplastic breast cancers (MpBC), there is limited expression of TROP2
Externí odkaz:
https://doaj.org/article/153c2e942072429c8da59c33c6ea4273
Autor:
Timothy P. DiPeri, MD, Timothy E. Newhook, MD, Ryan W. Day, MD, Yi-Ju Chiang, MSPH, Whitney L. Dewhurst, MS, AGNP-C, Elsa M. Arvide, MS, PA-C, Morgan L. Bruno, MS, ACNP-BC, Christopher P. Scally, MD, MS, Christina L. Roland, MD, MS, Matthew H.G. Katz, MD, Jean-Nicolas Vauthey, MD, George J. Chang, MD, MS, Brian D. Badgwell, MD, MS, Nancy D. Perrier, MD, Elizabeth G. Grubbs, MD, Jeffrey E. Lee, MD, Ching-Wei D. Tzeng, MD, Brian K. Bednarski, MD, Iris B. Chen, MS, APRN, Ryan J. Comeaux, MS, PA-C, Dana M. Cox, MPAS, PA-C, Barry W. Feig, MD, Sarah B. Fisher, MD, Keith F. Fournier, MD, Semhar J. Ghebremichael, MD, Heather M. Gibson, MS, PA-C, Nicole C. Gourmelon, MS, PA-C, Paul H. Graham, MD, Shannon Hancher, MD, Kelly K. Hunt, MD, Naruhiko Ikoma, MD, MPH, Shanae L. Ivey MPAS, PA-C, Emily Z. Keung, MD, Celia R. Ledet, MD, Angela R. Limmer, MS, PA-C, Paul F. Mansfield, MD, Lauren K. Mayon, MS, PA-C, Craig A. Messick, MD, Keyuri U. Popat, MD, Nikita F. Rajkot MPAS, PA-C, Justine L. Robinson MPAS, PA-C, Kristen A. Robinson MPAS, PA-C, Miguel A. Rodriguez-Bigas, MD, David A. Santos, MD, MS, John M. Skibber, MD, B. Bryce Speer, DO, Jose Soliz, MD, Matthew M. Tillman, MD, Keila E. Torres, MD, Antoinette van Meter, MD, Marla E. Weldon, MS, PA-C, Uduak Ursula Williams, MD, Y. Nancy You, MD, MHSc
Publikováno v:
Surgery Open Science, Vol 9, Iss , Pp 51-57 (2022)
Background: We designed a prospective feasibility study to assess the 5x-multiplier (5x) calculation (eg, 3 pills in last 24 hours × 5 = 15) to standardize discharge opioid prescriptions compared to usual care. Methods: Faculty-based surgical teams
Externí odkaz:
https://doaj.org/article/eb76d169a7434c548f83e4fa72a03946
Autor:
Timothy P. DiPeri, Mehmet Demirhan, Daniel D. Karp, Siqing Fu, David S. Hong, Vivek Subbiah, Joann Lim, Leomar Y. Ballester, Jean H. Tayar, Maria E. Suarez-Almazor, Milind Javle, Funda Meric-Bernstam
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 26-30 (2022)
Intrahepatic cholangiocarcinoma is a rare malignancy, which is rich in actionable alterations. Genomic aberrations in the mitogen-activated protein kinase (MAPK) pathway are common, and BRAF exon 15 p.V600E mutations are present in 5–7% of biliary
Externí odkaz:
https://doaj.org/article/be1451dee7c448a48031e47750b7ece3
Autor:
Kaushik Varadarajan, Christian X. Pico, Kurt Evans, Maria G. Raso, Yasmeen Rizvi, Xiaofeng Zheng, Timothy P. Diperi, Bailiang Wang, Stephen Scott, Ming Zhao, Argun Akcakanat, Antje M. Wengner, Timothy A. Yap, Funda Meric-Bernstam
Publikováno v:
Cancer Research. 83:6180-6180
Introduction: The ataxia telangiectasia and RAD3-related (ATR) kinase is a key component of the DNA damage response (DDR) and functions in conjunction with ataxia telangiectasia mutated (ATM). ATM loss or functional deficiency may enhance reliance on
Autor:
Timothy P. DiPeri, Timothy E. Newhook, Hop S. Tran Cao, Naruhiko Ikoma, Whitney L. Dewhurst, Elsa M. Arvide, Morgan L. Bruno, Matthew H.G. Katz, Jean-Nicolas Vauthey, Jeffrey E. Lee, Ching-Wei D. Tzeng
Publikováno v:
The Journal of surgical research. 278
As inpatient stays become shorter, one concern with standardizing discharge opioid prescriptions is the potential risk of "rebound refills." We sought to compare opioid prescription refill rates and volumes for surgical patients discharged on postope
Autor:
Ming Zhao, Timothy P. DiPeri, Gabriela Raso, Yasmeen Q. Rizvi, Xiaofeng Zheng, Kurt Evans, Argun Akcakanat, Fei Yang, Debu Tripathy, Ecaterina Ileana Dumbrava, Senthil Damodaran, Funda Meric-Bernstam
Publikováno v:
Cancer Research. 82:1791-1791
Purpose: TROP2 is overexpressed in many tumor types and is being actively pursued as a target. Sacituzumab govitecan (SG), a humanized anti-TROP2 antibody conjugated with SN-38, was approved for treatment of metastatic triple negative breast cancer,
Autor:
Niamh Coleman, Timothy P. DiPeri, Daniel Nguyen, Aung Naing, Sarina Anne Piha-Paul, Apostolia Maria Tsimberidou, Xiaofeng Zheng, Amber Johnson, Wanlin Wang, Kenna R. Shaw, Ecaterina Elena Dumbrava, Siqing Fu, Jordi Rodon Ahnert, David S. Hong, Vivek Subbiah, Timothy A. Yap, Rajyalakshmi Luthra, Keyur P. Patel, Funda Meric-Bernstam
Publikováno v:
Journal of Clinical Oncology. 40:3076-3076
3076 Background: The implementation of genomic profiling with next generation sequencing has revolutionized the field of precision oncology. Comprehensive genomic testing of tumors to identify actionable genomic alterations is now commonly performed
Autor:
Timothy P. DiPeri, Timothy E. Newhook, Ching-Wei D. Tzeng, Yun Shin Chun, Sunyoung S. Lee, Milind M. Javle, Jean-Nicolas Vauthey, Hop Sanderson Tran Cao
Publikováno v:
Journal of Clinical Oncology. 40:479-479
479 Background: Pre and post-operative elevation of serum CA 19-9 have been associated with poor outcomes and increased risk of recurrence in patients with resected intrahepatic cholangiocarcinoma (ICC). We sought to investigate the impact of CA 19-9